- Home
- ASM vs PSNL Comparison
ASM vs PSNL Comparison
Compare ASM & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASM | PSNL |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.7M | 872.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ASM | PSNL |
|---|---|---|
| Price | $6.10 | $8.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $5.27 | ★ $10.71 |
| AVG Volume (30 Days) | ★ 4.3M | 1.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 476.57 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $86,065,000.00 | $69,103,000.00 |
| Revenue This Year | $38.58 | N/A |
| Revenue Next Year | $39.81 | $20.33 |
| P/E Ratio | $43.59 | ★ N/A |
| Revenue Growth | ★ 58.42 | N/A |
| 52 Week Low | $0.85 | $2.83 |
| 52 Week High | $6.67 | $11.40 |
Technical Indicators
Market Signals| Indicator | ASM | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 66.42 | 44.25 |
| Support Level | $5.78 | $9.34 |
| Resistance Level | $6.42 | $9.85 |
| Average True Range (ATR) | 0.35 | 0.70 |
| MACD | 0.09 | -0.20 |
| Stochastic Oscillator | 82.62 | 5.19 |
Price Performance
Historical ComparisonAbout ASM Avino Silver & Gold Mines Ltd. (Canada)
Avino Silver & Gold Mines Ltd is a mineral resource company. It is engaged in the exploration, extraction, and processing of silver, gold, and copper and the acquisition, exploration, and advancement of mineral properties. The company generates majority of its revenues through the sale of Copper produced from its mines. Its project portfolio includes Avino; San Gonzalo; Oxide Tailings; Bralorne Gold and others.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.